Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
NCT02503462 · University Hospital, Basel, Switzerland · PHASE4 · terminated · last registry update 2017-02-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No additional patients fulfilling the inclusion criteria” | – | Registry record, University Hospital, Basel, Switzerland |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP3A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-01-23Phase 3 first posted: Gilead Sciences, B/F/TAF (NCT03405935)
- 2018-01-03Results posted on the registry: Gilead Sciences, STB + TVD (NCT02246998)
- 2018-01-02Also stopped (terminated): St Stephens Aids Trust, Microgynon 30® + Evotaz® (NCT02697851)
- 2017-09-15Results posted on the registry: Janssen Scientific Affairs, LLC, Darunavir + Ritonavir (NCT00855335)
- 2017-08-22Phase 3 first posted: ANRS, Emerging Infectious Diseases, Treatment discontinuation (NCT03256422)
- 2017-07-28Results posted on the registry: Massachusetts General Hospital, Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir) (NCT01929759)
- 2017-07-24Phase 3 first posted: Janssen Scientific Affairs, LLC, DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC (NCT03227861)
- 2017-07-02Results posted on the registry: Midtown Medical Center, Tampa, FL, Stribild (NCT02477527)
- 2017-06-12Results posted on the registry: Gilead Sciences, TAF + Placebo (NCT01967940)
- 2017-04-17Results posted on the registry: ViiV Healthcare, Maraviroc (Part 1) + Maraviroc (Part 2) (NCT02625207)
- 2017-04-10Results posted on the registry: Gilead Sciences, EVG/COBI/FTC/TDF (NCT01721109)
- 2016-12-23Results posted on the registry: Duke University, (FDC) ELV/COBI/FTC/TDF (NCT01694420)
- 2016-12-20Phase 3 first posted: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux, Genvoya (NCT02998320)
- 2016-12-09Phase 3 first posted: ANRS, Emerging Infectious Diseases, Dolutegravir + Darunavir-cobicistat (NCT02987530)
- 2016-11-01Results posted on the registry: Gilead Sciences, E/C/F/TAF + DRV (NCT01968551)
- 2016-04-14Results posted on the registry: Gilead Sciences, E/C/F/TAF + E/C/F/TDF (NCT01815736)
- 2016-04-11Results posted on the registry: Gilead Sciences, D/C/F/TAF + DRV (NCT01565850)
- 2016-04-04Results posted on the registry: Gilead Sciences, E/C/F/TAF (NCT02071082)
- 2016-03-14Phase 3 first posted: Gilead Sciences, E/C/F/TAF + F/R/TAF (NCT02707601)
- 2016-03-10Results posted on the registry: Gilead Sciences, E/C/F/TDF + ATV (NCT01705574)
- 2016-02-18Results posted on the registry: Gilead Sciences, E/C/F/TAF (NCT01818596)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision